Bristol Valuation

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

Do you wonder what the value of Bristol Myers Squibb is? Bristol Myers Cash and Equivalents Turnover is fairly stable at the moment as compared to the last year. Bristol Myers reported Cash and Equivalents Turnover of 2.72 in 2019. Net Cash Flow or Change in Cash and Cash Equivalents is likely to grow to about 6.4 B in 2020, whereas Free Cash Flow is likely to drop slightly above 6.1 B in 2020. Bristol Myers Squibb shows a prevailing Real Value of $62.09 per share. The current price of the firm is $60.21. At this time the firm appears to be fairly valued. This module approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Profit Margin of 0.0015 , Current Valuation of 78.11 B and Return On Equity of 0.0017  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Search Valuation

Bristol Myers Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Bristol Myers's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Fairly Valued
3rd of June 2020
Real Value
Bristol Myers is very steady asset. Calculation of real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol Myers Squibb time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Estimates (6)
LowProjected EPSHigh
LowEstimated ValueHigh
Annual Dividend
LowIncome Per ShareHigh
Consensus (13)
LowTarget PriceHigh


Bristol Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations

Bristol Valuation Data Drivers

Bristol valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Bristol equity instrument and the benefits of owning shares of Bristol Myers Squibb. Bristol Myers Net Current Assets as percentage of Total Assets are fairly stable at the moment as compared to the last year. Bristol Myers reported Net Current Assets as percentage of Total Assets of 8.50 in 2019. Asset Turnover is likely to grow to 0.43 in 2020, whereas Net Income Per Employee is likely to drop slightly above 106.8 K in 2020. View More Fundamentals
Average Assets    Average Equity    Enterprise Value    

Bristol Market Cap

Bristol Myers Squibb is rated below average in market capitalization category among related companies. Market capitalization of Drug Manufacturers?General industry is currently estimated at about 1.42 Trillion. Bristol Myers holds roughly 81.9 Billion in market capitalization claiming about 6% of equities under Drug Manufacturers?General industry.
Capitalization  Valuation  Revenue  Total debt  Workforce
Bristol Myers Squibb is rated below average in price to sales category among related companies. It is rated below average in last dividend paid category among related companies creating about  0.52  of Last Dividend Paid per Price to Sales. The ratio of Price to Sales to Last Dividend Paid for Bristol Myers Squibb is roughly  1.91 . Bristol Myers Dividend Yield is fairly stable at the moment as compared to the last year. Bristol Myers reported Dividend Yield of 0.026 in 2019. Dividends per Basic Common Share is likely to grow to 1.68 in 2020, whereas Payment of Dividends and Other Cash Distributions is likely to drop (2.9 B) in 2020.
 Dividends Paid 

About Bristol Myers Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of Bristol Myers Squibb on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Bristol Myers Squibb. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bristol Myers Squibb based exclusively on its fundamental and basic technical indicators. By analyzing Bristol Myers's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bristol Myers's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bristol Myers. We calculate exposure to Bristol Myers's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bristol Myers's related companies.
 2017 2018 2019 2020 (projected)
Consolidated Income975 M4.95 B3.46 B3.52 B
Direct Expenses6.07 B6.55 B8.08 B6.51 B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.

Bristol Valuation Basics

Bristol Myers Enterprise Value Fundamentals

Quick Ratio1.38
Revenue Growth82.10%
Payout Ratio273.02%
Enterprise Value To Ebitda14.46
Enterprise Value To Revenue5.40

Bristol Valuation Indicators

Bristol Myers Valuation Fundamental Ratios

Continue to Trending Equities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page